Bevacizumab for retinopathy of prematurity and neurodevelopment

J AAPOS. 2023 Feb;27(1):1-2. doi: 10.1016/j.jaapos.2023.01.002. Epub 2023 Jan 7.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Bevacizumab / therapeutic use
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Intravitreal Injections
  • Retinopathy of Prematurity* / drug therapy

Substances

  • Bevacizumab
  • Angiogenesis Inhibitors